Invention Grant
- Patent Title: Respiratory syncytial virus (RSV) vaccine
-
Application No.: US16168747Application Date: 2018-10-23
-
Publication No.: US11034729B2Publication Date: 2021-06-15
- Inventor: Thomas Kramps , Margit Schnee , Daniel Voss , Benjamin Petsch
- Applicant: CureVac AG
- Applicant Address: DE Tübingen
- Assignee: CureVac AG
- Current Assignee: CureVac AG
- Current Assignee Address: DE Tübingen
- Agency: Parker Highlander PLLC
- Priority: WOPCT/EP2013/002518 20130821
- Main IPC: A61K39/155
- IPC: A61K39/155 ; C07K16/10 ; C07K14/005 ; A61K39/12 ; C12N7/00 ; A61K39/00 ; A61K48/00

Abstract:
The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.
Public/Granted literature
- US20190144508A1 RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE Public/Granted day:2019-05-16
Information query